



GUJARAT THEMIS BIOSYN LIMITED

REGD. OFFICE & FACTORY : 69/C, GIDC, INDUSTRIAL ESTATE,,
VAPI-396 195. DIST. VALSAD. GUJARAT, INDIA.
TEL: 0260-2430027 • FAX : 0260-2100639
Email : hrm@gtbl.co.in
CIN No.: L24230GJ1981PLC004878

GTBL: CS: 2016-17:

11th May, 2016

The General Manager
Dept. of Corporate Services
Bombay Stock Exchange Ltd.
Rotunda Building, 1st Floor,
Mumbai Samachar Marg,
Mumbai - 400 001

Dear Sir/Madam,

SUB: AUDITED FINANCIAL RESULTS FOR THE QUARTER/FINANCIAL YEAR ENDED 31ST MARCH, 2016.

The Board of Directors at its meeting held on Wednesday, May 11th, 2016, considered and approved Audited Financial Results for the Quarter/Financial Year ended 31st March, 2016 which were recommended by the Audit Committee.

A copy of Audited Financial Results for the Quarter/Financial Year ended 31st March, 2016 is enclosed for your perusal.

This may be taken as compliance of the Listing Agreement; the Company has entered with your stock exchange.

Kindly acknowledge.

Thanking you,
Yours faithfully,

For **GUJARAT THEMIS BIOSYN LTD**

VIKAS P. TAREKAR
COMPANY SECRETARY



GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: admin@gtbl.co.in Wbsite: www.gtbl.in

Statement of Audited Financial Results for the Year ended March 31, 2016

(Rs. in Lacs)

	Particulars	Quarter Ended			Year Ended	
		31-Mar-16	31-Dec-15	31-Mar-15	31-Mar-16	31-Mar-15
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
1	Income from operations					
	(a) Net sales/income from operations (Net of excise duty)	825.83	785.35	804.89	3,262.47	3,144.02
	(b) Other operating income	-	-	-	-	-
	Total income from operations (net)	825.83	785.35	804.89	3,262.47	3,144.02
2	Expenses					
	(a) Cost of raw materials consumed	7.96	7.74	6.46	32.14	28.99
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefits expense	104.62	107.77	109.20	427.57	400.20
	(e) Depreciation and amortisation expense	30.52	30.48	31.96	119.87	137.54
	(f) Other expenses					
	i) Stores & Spares	58.24	54.89	55.35	204.81	177.10
	ii) Power	314.83	306.31	294.50	1,278.80	1,158.45
	iii) Fuel	85.50	97.33	104.00	384.71	410.99
	iv) Water	10.24	13.15	11.76	51.43	46.25
	v) Other Expenditure	67.88	66.71	100.92	279.47	295.25
	Total Expenses	679.80	684.38	714.14	2,778.79	2,654.77
3	Profit / (Loss) from operations before other income,finance costs and exceptional items(1 - 2)	146.03	100.97	90.74	483.68	489.25
4	Other income	4.37	2.42	2.09	17.00	8.88
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	150.40	103.39	92.83	500.68	498.13
6	Finance costs	11.32	10.82	8.17	37.75	38.72
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	139.08	92.57	84.66	462.93	459.41
8	Exceptional items	-	-	-	-	-
9	Net Profit from ordinary activities before tax (7 - 8)	139.08	92.57	84.66	462.93	459.41
10	Tax expense	-	-	-	-	-
11	Net Profit from ordinary activities after tax (9 - 10)	139.08	92.57	84.66	462.93	459.41
12	Extraordinary items (net of tax expense)	-	-	-	-	-
13	Net Profit for the period (11 - 12)	139.08	92.57	84.66	462.93	459.41
14	Paid-up equity share capital Face Value Rs.5/- per share each	726.40	726.40	726.40	726.40	726.40
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				(342.00)	(804.93)
16.i	Earnings per share (before Extraordinary items) Face Value Rs.5/- per share each (not annualised):					
	(a) Basic	0.96	0.64	0.58	3.19	3.16
	(b) Diluted	0.96	0.64	0.58	3.19	3.16
16.ii	Earnings per share (after Extraordinary items) Face Value Rs.5/- per share each (not annualised):					
	(a) Basic	0.96	0.64	0.58	3.19	3.16
	(b) Diluted	0.96	0.64	0.58	3.19	3.16

See accompanying notes to Financial Results



Notes :

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at its their respective meetings held on May 11, 2016.
- 2 The Company is mainly engaged in the business of manufacturing Bulk Drugs. Hence, there is no separate reportable segment as per Accounting Standard - 17 (AS-17) "Segment Reporting".
- 3 The figures for the last quarter ended March 31, 2016 and March 31, 2015 are balancing figures between the audited figures in respect of the full financial year and published year to date figures upto the third quarter of the relevant financial year.
- 4 In view of carry forward losses / unabsorbed depreciation of earlier years, company being a sick company and relief & concession granted by the BIFR, no provision for the Income Tax has been made on profit of the year.
- 5 In respect of Auditor's qualifications / observations in the Audit Report for the year ended March 31, 2016 that,
 - a) The outstanding balance as at March 31, 2016, in respect of certain balances of loans & advances, liability for expenses, trade payables and creditors for capital expenditure are subject to confirmation and adjustments necessary upon reconciliation if any, consequential impact thereof in the financial statements is not ascertainable. The Management does not expect any material variation in the financial statements.
 - b) The Company has filed Miscellaneous Application before Hon'ble BIFR on February 5, 2016 for deregistration of the Company from BIFR under SICA as the Company's Net worth has turned positive during the financial year 2015-16. The Company is hopeful that its application will be approved and the company shall be deregistered from BIFR. In view of sufficient cash profit generated by the Company, the Company has made request to BIFR that new promoter Themis Medicare Limited may be allowed to withdraw their non-interest bearing unsecured loan of INR 350 lacs. However, pending approval from BIFR, the Company has made repayment of Rs. 205.99 lacs against the said loan on demand by Themis Medicare Limited.
 - c) The Company is in the process of determining and identifying significant components of fixed assets as prescribed under the provisions of para 4(a) under the heading Notes after Part C in Schedule II of the Companies Act, 2013 and hence no effect of the same has been given in the financial result for the year ended March 31, 2016. Management expects that this would not have a material impact on depreciation for the quarter and year ended March 31, 2016.
- 6 The Company has accumulated losses of Rs. 574.12 lacs leaving Net Worth of the Company of Rs. 384.40 lacs as at March 31, 2016. Further, the Company also has a working capital deficiency. The Company has been registered with the Board for Industrial & Financial Reconstruction (BIFR). Further the Rehabilitation Scheme had been sanctioned by the Board for Industrial and Financial Reconstruction (BIFR) in the hearing held January 12, 2012. The Company has initiated efforts including development of new products and has ventured into manufacturing of goods on own and on job work basis so as to reduce the losses. The Company has made profit for year ended March 31, 2016 and previous year 2014-15, 2013-14, 2012-13 & 2011-12. Accordingly, these accounts have been prepared on a going concern basis.
- 7 The figures of previous period / year have been regrouped / rearranged wherever necessary / practicable to conform to current period presentation.



By order of the Board of Directors
For GUJARAT THEMIS BIOSYN LTD.


Dr. DINESH PATEL
Chairman

Place : Mumbai

Date : May 11, 2016

GUJARAT THEMIS BIOSYN LIMITED
CIN: L24230GJ1981PLC004878
69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

STATEMENT OF ASSETS & LIABILITIES AS AT MARCH 31, 2016

(Rs. in Lacs)

Particulars	As at	
	31-Mar-16 (Audited)	31-Mar-15 (Audited)
A. EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share Capital	726.40	726.40
(b) Reserves and Surplus	(342.00)	(804.93)
(c) Money received against share warrants	-	-
Sub-total-Share holders' Funds	384.40	(78.54)
2 Share application money pending allotment	-	-
3 Non-Current Liabilities		
(a) Long-Term Borrowings	105.15	528.35
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other long term liabilities	-	-
(d) Long-Term Provisions	46.68	40.74
Sub-total-Non-current liabilities	151.83	569.09
4 Current Liabilities		
(a) Short-Term Borrowings	9.90	0.00
(b) Trade Payables	550.62	564.61
(c) Other Current Liabilities	363.42	412.54
(d) Short-Term Provisions	7.70	3.55
Sub-total-current liabilities	931.64	980.69
TOTAL - EQUITY AND LIABILITIES	1,467.86	1,471.25
B. ASSETS		
1 Non-Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	937.00	971.36
(ii) Intangible Assets	-	-
(b) Capital Work-In-Progress	4.08	2.76
(c) Non-Current Investments	0.50	0.56
(d) Long-Term Loans And Advances	176.12	130.09
(e) Trade Receivables	-	-
(f) Other Non-Current Assets	29.46	18.97
Sub-total-Non-Current Assets	1,147.16	1,123.74
2 Current Assets		
(a) Current investments	-	-
(b) Inventories	41.63	33.24
(c) Trade Receivables	216.48	237.15
(d) Cash and Cash Equivalents	18.96	22.93
(e) Short-Term Loans And Advances	43.63	54.15
(f) Other Current Assets	-	0.04
Sub-total-Current Assets	320.70	347.51
TOTAL- ASSETS	1,467.86	1,471.25